Phosphoinositide 3-kinase γ inhibits cardiac GSK-3 independently of Akt

Science Signaling

Volumn 6, Issue 259, 2013, Pages

  Mohan, Maradumane L ^a   Jha, Babal K ^a   Gupta, Manveen K ^a   Vasudevan, Neelakantan T ^a   Martelli, Elizabeth E ^a   Mosinski, John David ^a   Naga Prasad, Sathyamangla V ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE 2A METHYLTRANSFERASE PPMT 1; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HEART MUSCLE CELL; HEART SIZE; HEART VENTRICLE HYPERTROPHY; INSULIN TREATMENT; MOUSE; NONHUMAN; NUCLEAR EXPORT SIGNAL; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TRANSGENE;

ANIMALS; CARBOXYLIC ESTER HYDROLASES; CARDIOMEGALY; CLASS IB PHOSPHATIDYLINOSITOL 3-KINASE; ENZYME ACTIVATION; GLYCOGEN SYNTHASE KINASE 3; HEK293 CELLS; HUMANS; MICE; MICE, KNOCKOUT; MUSCLE PROTEINS; MYOCARDIUM; NFATC TRANSCRIPTION FACTORS; PROTO-ONCOGENE PROTEINS C-AKT;

MUS;

EID: 84872738779     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2003308     Document Type: Article

References (50)

1. F. Damilano, A. Perino, E. Hirsch, PI3K kinase and scaffold functions in heart. Ann. N. Y. Acad. Sci. 1188, 39-45 (2010).
2. B. Vanhaesebroeck, S. J. Leevers, K. Ahmadi, J. Timms, R. Katso, P. C. Driscoll, R. Woscholski, P. J. Parker, M. D. Waterfield, Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70, 535-602 (2001).
3. B. Vanhaesebroeck, J. Guillermet-Guibert, M. Graupera, B. Bilanges, The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329-341 (2010).
4. D. Carnevale, G. Lembo, PI3Kγ in hypertension: A novel therapeutic target controlling vascular myogenic tone and target organ damage. Cardiovasc. Res. 95, 403-408 (2012).
5. T. Sasaki, J. Irie-Sasaki, R. G. Jones, A. J. Oliveira-dos-Santos, W. L. Stanford, B. Bolon, A. Wakeham, A. Itie, D. Bouchard, I. Kozieradzki, N. Joza, T. W. Mak, P. S. Ohashi, A. Suzuki, J. M. Penninger, Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science 287, 1040-1046 (2000).
6. M. A. Crackower, G. Y. Oudit, I. Kozieradzki, R. Sarao, H. Sun, T. Sasaki, E. Hirsch, A. Suzuki, T. Shioi, J. Irie-Sasaki, R. Sah, H. Y. Cheng, V. O. Rybin, G. Lembo, L. Fratta, A. J. Oliveira-dos-Santos, J. L. Benovic, C. R. Kahn, S. Izumo, S. F. Steinberg, M. P. Wymann, P. H. Backx, J. M. Penninger, Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110, 737 -749 (2002).
7. J. R. McMullen, T. Shioi, L. Zhang, O. Tarnavski, M. C. Sherwood, P. M. Kang, S. Izumo, Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 100, 12355-12360 (2003).
8. S. V. Naga Prasad, G. Esposito, L. Mao, W. J. Koch, H. A. Rockman, Gβγ-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J. Biol. Chem. 275, 4693-4698 (2000).
9. E. Patrucco, A. Notte, L. Barberis, G. Selvetella, A. Maffei, M. Brancaccio, S. Marengo, G. Russo, O. Azzolino, S. D. Rybalkin, L. Silengo, F. Altruda, R. Wetzker, M. P. Wymann, G. Lembo, E. Hirsch, PI3Kγ modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118, 375-387 (2004).
10. J. J. Nienaber, H. Tachibana, S. V. Naga Prasad, G. Esposito, D. Wu, L. Mao, H. A. Rockman, Inhibition of receptor-localized PI3K preserves cardiac β-adrenergic receptor function and ameliorates pressure overload heart failure. J. Clin. Invest. 112, 1067-1079 (2003).
11. N. T. Vasudevan, M. L. Mohan, M. K. Gupta, A. K. Hussain, S. V. Naga Prasad, Inhibition of protein phosphatase 2A activity by PI3Kγ regulates β-adrenergic receptor function. Mol. Cell 41, 636-648 (2011).
12. S. V. Naga Prasad, S. A. Laporte, D. Chamberlain, M. G. Caron, L. Barak, H. A. Rockman, Phosphoinositide 3-kinase regulates β2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/β-arrestin complex. J. Cell Biol. 158, 563-575 (2002).
13. S. V. Naga Prasad, A. Jayatilleke, A. Madamanchi, H. A. Rockman, Protein kinase activity of phosphoinositide 3-kinase regulates β-adrenergic receptor endocytosis. Nat. Cell Biol. 7, 785-796 (2005).
14. R. Dhand, I. Hiles, G. Panayotou, S. Roche, M. J. Fry, I. Gout, N. F. Totty, O. Truong, P. Vicendo, K. Yonezawa, M. Kasuga, S. A. Courtneidge, M. D. Waterfield, PI 3-kinase is a dual specificity enzyme: Autoregulation by an intrinsic protein-serine kinase activity. EMBO J. 13, 522-533 (1994).
15. E. Hirsch, L. Braccini, E. Ciraolo, F. Morello, A. Perino, Twice upon a time: PI3K's secret double life exposed. Trends Biochem. Sci. 34, 244-248 (2009).
16. C. Costa, E. Hirsch, More than just kinases: The scaffolding function of PI3K. Curr. Top. Microbiol. Immunol. 346, 171-181 (2010).
17. 3 and cAMP signaling through a PKA anchoring function of p110γ. Mol. Cell 42, 84-95 (2011).
18. B. W. Doble, J. R. Woodgett, GSK-3: Tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116, 1175- 1186 (2003).
19. C. A. Grimes, R. S. Jope, The multifaceted roles of glycogen synthase kinase 3β in cellular signaling. Prog. Neurobiol. 65, 391-426 (2001).
20. V. Stambolic, J. R. Woodgett, Mitogen inactivation of glycogen synthase kinase-3β in intact cells via serine 9 phosphorylation. Biochem. J. 303 (Pt. 3), 701- 704 (1994).
21. V. Janssens, J. Goris, Protein phosphatase 2A: A highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 353, 417-439 (2001).
22. M. Mumby, A new role for protein methylation: Switching partners at the phosphatase ball. Sci. STKE 2001, pe1 (2001).
23. V. Stanevich, L. Jiang, K. A. Satyshur, Y. Li, P. D. Jeffrey, Z. Li, P. Menden, M. F. Semmelhack, Y. Xing, The structural basis for tight control of PP2A methylation and function by LCMT-1. Mol. Cell 41, 331-342 (2011).
24. H. Xie, S. Clarke, Methyl esterification of C-terminal leucine residues in cytosolic 36-kDa polypeptides of bovine brain. A novel eucaryotic protein carboxyl methylation reaction. J. Biol. Chem. 268, 13364-13371 (1993).
25. H. Xie, S. Clarke, An enzymatic activity in bovine brain that catalyzes the reversal of the C-terminal methyl esterification of protein phosphatase 2A. Biochem. Biophys. Res. Commun. 203, 1710-1715 (1994).
26. H. Xie, S. Clarke, Protein phosphatase 2A is reversibly modified by methyl esterification at its C-terminal leucine residue in bovine brain. J. Biol. Chem. 269, 1981-1984 (1994).
27. I. De Baere, R. Derua, V. Janssens, C. Van Hoof, E. Waelkens, W. Merlevede, J. Goris, Purification of porcine brain protein phosphatase 2A leucine carboxyl methyltransferase and cloning of the human homologue. Biochemistry 38, 16539-16547 (1999).
28. J. Lee, J. Stock, Protein phosphatase 2A catalytic subunit is methyl-esterified at its carboxyl terminus by a novel methyltransferase. J. Biol. Chem. 268, 19192-19195 (1993).
29. J. Lee, Y. Chen, T. Tolstykh, J. Stock, A specific protein carboxyl methylesterase that demethylates phosphoprotein phosphatase 2A in bovine brain. Proc. Natl. Acad. Sci. U.S.A. 93, 6043- 6047 (1996).
30. K. Ban, A. J. Cooper, S. Samuel, A. Bhatti, M. Patel, S. Izumo, J. M. Penninger, P. H. Backx, G. Y. Oudit, R. G. Tsushima, Phosphatidylinositol 3-kinase γ is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ. Res. 103, 643-653 (2008).
31. C. L. Antos, T. A. McKinsey, N. Frey, W. Kutschke, J. McAnally, J. M. Shelton, J. A. Richardson, J. A. Hill, E. N. Olson, Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U.S.A. 99, 907- 912 (2002).
32. S. Haq, G. Choukroun, Z. B. Kang, H. Ranu, T. Matsui, A. Rosenzweig, J. D. Molkentin, A. Alessandrini, J. Woodgett, R. Hajjar, A. Michael, T. Force, Glycogen synthase kinase-3β is a negative regulator of cardiomyocyte hypertrophy. J. Cell Biol. 151, 117 -130 (2000).
33. J. M. Beaulieu, R. R. Gainetdinov, M. G. Caron, The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol. Sci. 28, 166-172 (2007).
34. G. Y. Oudit, H. Sun, B. G. Kerfant, M. A. Crackower, J. M. Penninger, P. H. Backx, The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J. Mol. Cell. Cardiol. 37, 449-471 (2004).
35. PP2A. Two potent protein phosphatase 2A-specific inhibitor proteins. Methods Mol. Biol. 93, 59-66 (1998).
36. Y. Xing, Z. Li, Y. Chen, J. B. Stock, P. D. Jeffrey, Y. Shi, Structural mechanism of demethylation and inactivation of protein phosphatase 2A. Cell 133, 154-163 (2008).
37. D. G. Myszka, Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. Curr. Opin. Biotechnol. 8, 50-57 (1997).
38. A. S. Armand, M. Bourajjaj, S. Martínez-Martínez, H. el Azzouzi, P. A. da Costa Martins, P. Hatzis, T. Seidler, J. M. Redondo, L. J. De Windt, Cooperative synergy between NFAT and MyoD regulates myogenin expression and myogenesis. J. Biol. Chem. 283, 29004 -29010 (2008).
39. B. Sanna, O. F. Bueno, Y. S. Dai, B. J. Wilkins, J. D. Molkentin, Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth. Mol. Cell. Biol. 25, 865-878 (2005).
40. D. A. Cross, D. R. Alessi, P. Cohen, M. Andjelkovich, B. A. Hemmings, Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789 (1995).
41. H. Eldar-Finkelman, R. Seger, J. R. Vandenheede, E. G. Krebs, Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells. J. Biol. Chem. 270, 987-990 (1995).
42. X. Fang, S. X. Yu, Y. Lu, R. C. Bast Jr., J. R. Woodgett, G. B. Mills, Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc. Natl. Acad. Sci. U.S.A. 97, 11960-11965 (2000).
43. N. Goode, K. Hughes, J. R. Woodgett, P. J. Parker, Differential regulation of glycogen synthase kinase-3β by protein kinase C isotypes. J. Biol. Chem. 267, 16878-16882 (1992).
44. M. Li, X. Wang, M. K. Meintzer, T. Laessig, M. J. Birnbaum, K. A. Heidenreich, Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3β. Mol. Cell. Biol. 20, 9356-9363 (2000).
45. C. Sutherland, I. A. Leighton, P. Cohen, Inactivation of glycogen synthase kinase-3β by phosphorylation: New kinase connections in insulin and growth-factor signalling. Biochem. J. 296 (Pt. 1), 15-19 (1993).
46. M. Siragusa, R. Katare, M. Meloni, F. Damilano, E. Hirsch, C. Emanueli, P. Madeddu, Involvement of phosphoinositide 3-kinase γ in angiogenesis and healing of experimental myocardial infarction in mice. Circ. Res. 106, 757-768 (2010).
47. B. J. Haubner, G. G. Neely, J. G. Voelkl, F. Damilano, K. Kuba, Y. Imai, V. Komnenovic, A. Mayr, O. Pachinger, E. Hirsch, J. M. Penninger, B. Metzler, PI3Kγ protects from myocardial ischemia and reperfusion injury through a kinase-independent pathway. PLoS One 5, e9350 (2010).
48. P. H. Sugden, S. J. Fuller, S. C. Weiss, A. Clerk, Glycogen synthase kinase 3 (GSK3) in the heart: A point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br. J. Pharmacol. 153 (Suppl. 1), S137-S153 (2008).
49. P. Zhai, S. Gao, E. Holle, X. Yu, A. Yatani, T. Wagner, J. Sadoshima, Glycogen synthase kinase-3α reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases. J. Biol. Chem. 282, 33181-33191 (2007).
50. C. Perrino, S. V. Naga Prasad, L. Mao, T. Noma, Z. Yan, H. S. Kim, O. Smithies, H. A. Rockman, Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J. Clin. Invest. 116, 1547-1560 (2006).